Overexpression of EGFR predicts a poor prognosis in many cancers, particularly in head and neck squamous cell carcinomas (Santini et al, 1991; Dassonville et al, 1993; Salomon et al, 1995; Maurizi et al, 1996; Grandis et al, 1996, 1998; Etienne et al, 1999), and consequently EGFR is a prime target for anticancer therapy. Here, EGFR is linked to head and neck squamous cell carcinoma.